ESMO Congress 2021: highlights from the EORTC gastrointestinal tract cancer group’s perspective

Altres autors/es

Institut Català de la Salut

[Koessler T] Department of Oncology, Geneva University Hospital, Geneva, Switzerland. Swiss Cancer Center Leman (SCCL), University of Geneva, Lausanne, Switzerland. [Alsina M] Hospital Universitario de Navarra (HUN), Medical Oncology Department, Pamplona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Arnold D] Department of Oncology, Haematology and Palliative Care, Asklepios Klinik Altona, Asklepios Tumorzentrum Hamburg, Hamburg, Germany. [Ben-Aharon I] Division of Oncology, Rambam Health Care Campus, Rappaport Faculty of Medicine, Technion, Haifa, Israel. [Collienne M] Department of Oncology, Haematology and Palliative Care, Asklepios Klinik Altona, Asklepios Tumorzentrum Hamburg, Hamburg, Germany. European Organisation for Research and Treatment of Cancer, Brussels, Belgium. [Lutz MP] Caritasklinikum, Saarbrucken, Germany

Vall d'Hebron Barcelona Hospital Campus

Data de publicació

2022-10-28T12:42:25Z

2022-10-28T12:42:25Z

2022-04



Resum

Neuroendocrine tumours; Pancreatic cancer; Stomach cancer


Tumores neuroendocrinos; Cáncer de páncreas; Cáncer de estómago


Tumors neuroendocrins; Càncer de pàncrees; Càncer d'estómac


There has been no major change of practice in gastrointestinal oncology at the European Society for Medical Oncology (ESMO) symposium 2021, but confirmation that immunotherapy in combination with chemotherapy has become standard of care in several indications. The European Organisation for Research and Treatment of Cancer (EORTC) Gastrointestinal Track Cancer Group has selected important phase II and III trials presented during the symposium across all gastrointestinal cancers as well as early reports on new drugs or new combinations that may change practice in the future.


This work was supported by a donation from the Swiss Cancer Research Foundation from Switzerland. MC was supported by a grant by EORTC Cancer Research Fund (ECRF) and the Gastrointestinal Tract Cancer Group.

Tipus de document

Article


Versió publicada

Llengua

Anglès

Publicat per

Elsevier

Documents relacionats

ESMO Open;7(2)

https://doi.org/10.1016/j.esmoop.2022.100392

Citació recomanada

Aquesta citació s'ha generat automàticament.

Drets

Attribution 4.0 International

http://creativecommons.org/licenses/by/4.0/

Aquest element apareix en la col·lecció o col·leccions següent(s)